Ac-KE-NH₂ and NFκB in Periodontal Disease

Periodontal disease as immune dysregulation

The Page-Schroeder model frames periodontal disease as a tissue destruction process driven primarily by host inflammatory response, not bacterial load alone. Continued biofilm presence triggers a sustained NFκB-mediated cytokine cascade in periodontal tissue: IL-1β and TNF-α drive matrix degradation; RANKL drives osteoclast activation and alveolar bone resorption.

NFκB as the upstream lever

NFκB (Nuclear Factor κ-light-chain-enhancer of activated B cells) is the master transcription factor coordinating the inflammatory cascade. Modulating NFκB activity directly addresses the upstream signal driving downstream IL-1β, TNF-α, and RANKL production. This is mechanistically distinct from antimicrobial therapy, which addresses biofilm without affecting host response.

Ac-KE-NH₂ activity profile

KE (Lys-Glu, also known as Vilon) is a thymic dipeptide originally characterized as an immune homeostasis bioregulator. Published research (Khavinson et al., Front Genet 2019) describes its NFκB-modulating activity. The Ac-KE-NH₂ analog used in OptiOral Care formulations carries the dual-terminus modification — N-terminal acetylation and C-terminal amidation — that enables therapeutic exposure from a non-injectable oral format.

Long-term human cohort data

A 6-year prospective study of 266 elderly subjects published by Khavinson and Morozov (Neuroendocrinology Letters 2003) documented a 4.1-fold reduction in mortality with normalization of immune and metabolic indices following peptide bioregulator administration including the KE-class compound. Zero adverse events were reported across the cohort.

Citations

1. Khavinson VKh et al. Peptide regulation of NFκB pathway and immune homeostasis. Front Genet. 2019.
2. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-40.